Cargando…

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response

SIMPLE SUMMARY: The use of biologic agents in the treatment of immune adverse events (irAEs) due to immune checkpoint inhibitors has been an attractive option but there are limited data on their impact on tumor progression. This study is one of the largest retrospective cohorts that evaluated the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parvathareddy, Vishnupriyadevi, Selamet, Umut, Sen, Aditi A., Mamlouk, Omar, Song, Juhee, Page, Valda D., Abdelrahim, Maen, Diab, Adi, Abdel-Wahab, Noha, Abudayyeh, Ala
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649345/ https://www.ncbi.nlm.nih.gov/pubmed/37958355 http://dx.doi.org/10.3390/cancers15215181

Ejemplares similares

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury
por: Abudayyeh, Ala, et al.
Publicado: (2022)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

RNAi and cancer: Implications and applications
por: Abdelrahim, Maen, et al.
Publicado: (2006)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?
por: Abudayyeh, Ala, et al.
Publicado: (2015)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma
por: Hedrick, Erik, et al.
Publicado: (2015)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
por: Fa'ak, Faisal, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
por: Abdel-Wahab, Noha, et al.
Publicado: (2016)

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H., et al.
Publicado: (2019)

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
por: Elsayed, Marwa, et al.
Publicado: (2021)

Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients
por: Antonio, João Roberto, et al.
Publicado: (2016)

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2021)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Transplant Oncology: An Evolving Field in Cancer Care
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Editorial: Women in onconephrology: 2022
por: Abudayyeh, Ala, et al.
Publicado: (2023)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

Psychiatric Adverse Events Associated With Infliximab: A Cohort Study From the French Nationwide Discharge Abstract Database
por: Thillard, Eve-Marie, et al.
Publicado: (2020)

Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system
por: Lee, Jeong-Eun, et al.
Publicado: (2022)

Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer
por: Arain, Abeer, et al.
Publicado: (2020)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Transplant Oncology: An Emerging Discipline of Cancer Treatment
por: Abdelrahim, Maen, et al.
Publicado: (2023)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u2osnv50raj0eqovqp1juil6b4